|
|
News Breaks | | | | October 9, 2012 | | 09:05 EDT |  | NAVB | Navidea announces peer-reviewed publication from clinical trial of Lymphoseek
Navidea Biopharmaceuticals announced the peer-reviewed publication of results from two Phase 3 clinical trials of Lymphoseek Injection in patients with melanoma of the skin. The trials assessed the performance of Lymphoseek against the standard of care, vital blue dye, in lymphatic mapping. Results demonstrated that Lymphoseek met its primary efficacy endpoint of rate of agreement, or concordance, with VBD. Lymphoseek is a receptor-targeted radiopharmaceutical under development for use in lymphatic mapping, a procedure in which key lymph nodes adjacent to a primary tumor, that may contain tumor metastases, are identified and biopsied to determine if cancer has spread to these lymph nodes. The study, "Combined Analysis of Phase III Trials Evaluating Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma," was published in the current online edition of the journal Annals of Surgical Oncology. | |
|
News For NAVB From The Last 14 Days Check below for free stories on NAVB the last two weeks. |
|
|
| May 15, 2013 | | 16:37 EDT | | NAVB | Nordion signs contract manufacturing agreement with Navidea
 Subscribe for More Information | |
|
|
|
|
|
|
